Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359077 | 1.00 | FFAR3 (0.39) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| SCHEMBL369709 | 1.00 | FFAR3 (0.39) | FFAR3TSHRNFKB1CYP2C19USP2 | |
| Hydrochloric Acid SCHEMBL19022235 | 0.98 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL19022236 | 0.98 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL17171332 | 0.93 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL17157178 | 0.93 | FFAR3 (0.37) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL27092759 | 0.91 | FFAR3 (0.36) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL28616020 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL11303377 | 0.84 | FFAR3 (0.40) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11303374 | 0.84 | FFAR3 (0.40) | FFAR3TSHRNFKB1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4074328-A1 | INTERMEDIATES OF CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | Seagen Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3634961-B1 | (4-(([1,2,4]TRIAZOLO[4,3-A]PYRIDINE-6-YL)OXY)-1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)UREIDO DERIVATIVES AS ANTI-INFLAMMATORY P38 MAPK INHIBITORS FOR TREATING DISEASES OF THE RESPIRATORY TRACT | CHIESI FARM SPA (IT) | 2021-05-26 | — | — | EP | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2013072813-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013072813-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| CN-102372698-A | Phthalazinone derivative and its preparation method and use in medicine | JIANGSU HENGRUI MEDICINE CO | 2012-03-14 | — | — | CN | disclosed |
| US-7989634-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-08-02 | — | — | US | disclosed |
| WO-2002064559-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | FFAR3 1191/4885TSHR 2355/4885NFKB1 1767/4885 |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | FFAR3 2929/4885TSHR 1886/4885NFKB1 1514/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | FFAR3 2702/4885TSHR 1824/4885NFKB1 2074/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | FFAR3 2929/4885TSHR 1886/4885NFKB1 1514/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | FFAR3 2929/4885TSHR 1886/4885NFKB1 1514/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | FFAR3 2929/4885TSHR 1886/4885NFKB1 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.